Future oncology (London, England) · 2021
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
Протокол клинического исследованияСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Verstovsek Srdan, Chen Chih-Cheng, Egyed Miklós, Ellis Martin, Fox Laura, Goh Yeow T, Gupta Vikas, Harrison Claire, Kiladjian Jean-Jacques, Lazaroiu Mihaela C, Mead Adam, McLornan Donal, McMullin Mary F, Oh Stephen T, Perkins Andrew, Platzbecker Uwe, Scheid Christof, Vannucchi Alessandro, Yoon Sung-Soo, Kowalski Mark M, Mesa Ruben A
Аннотация
Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB.
Предметные рубрики MeSH
Activin Receptors, Type IAdministration, OralAdultBenzamidesClinical Trials, Phase III as TopicDanazolDouble-Blind MethodFemaleHumansJanus Kinase 1Janus Kinase 2Janus Kinase InhibitorsMaleMiddle AgedPrimary MyelofibrosisPyrimidinesRandomized Controlled Trials as TopicSelf AdministrationTreatment Outcome